Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

被引：0
|
作者：
W Chua
D Goldstein
C K Lee
H Dhillon
M Michael
P Mitchell
S J Clarke
B Iacopetta
机构：
[1] Sydney Cancer Centre,Department of Medical Oncology
[2] Concord Repatriation General Hospital,Department of Medical Oncology
[3] Prince of Wales Hospital,Division of Haematology and Medical Oncology
[4] NHMRC Clinical Trials Centre,Department of Medical Oncology
[5] Centre of Medical Psychology and Evidence-based Decision-Making,undefined
[6] University of Sydney,undefined
[7] Peter MacCallum Cancer Centre,undefined
[8] Austin Hospital,undefined
[9] School of Surgery,undefined
[10] University of Western Australia,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; metastatic; chemotherapy; predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：998 / 1004
页数：6
相关论文
共 50 条
  • [31] Chemotherapy in metastatic colorectal cancer
    Christopoulou A.
    Techniques in Coloproctology, 2004, 8 (Suppl 1) : S43 - S46
  • [32] Chemotherapy of metastatic colorectal cancer
    Saad E.D.
    Hoff P.M.
    Current Treatment Options in Gastroenterology, 2005, 8 (3) : 239 - 247
  • [33] Chemotherapy in metastatic colorectal cancer
    Kelly, Claire
    Cassidy, Jim
    SURGICAL ONCOLOGY-OXFORD, 2007, 16 (01): : 65 - 70
  • [34] Chemotherapy of metastatic colorectal cancer
    Modest, D. P.
    Hiddemann, W.
    Heinemann, V.
    INTERNIST, 2014, 55 (01): : 37 - 42
  • [35] Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh, Kwang Wook
    Kim, Joo Hyung
    Kim, Do Yoon
    Kim, Young Bae
    Lee, Chulho
    Choi, Sungho
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (11) : 1379 - 1385
  • [36] Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?
    Kwang Wook Suh
    Joo Hyung Kim
    Do Yoon Kim
    Young Bae Kim
    Chulho Lee
    Sungho Choi
    Annals of Surgical Oncology, 2006, 13 : 1379 - 1385
  • [37] Therapy monitoring with FDG-PET in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss, A
    Rudi, J
    Strauss, LG
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 113P - 113P
  • [38] Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, MTHFR or XRCC1 gene?
    Kim, DY
    Kim, YB
    Choi, HS
    Kim, JM
    Suh, K
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 7 - 7
  • [39] Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
    Otsu, Satoshi
    Hirashima, Yoshinori
    Nishikawa, Kazuo
    Sakashita, Hiroyuki
    Morinaga, Ryotaro
    Watanabe, Koichiro
    Shirao, Kuniaki
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 19 - 23
  • [40] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
    Lievre, Astrid
    Samalin, Emmanuelle
    Mitry, Emmanuel
    Assenat, Eric
    Boyer-Gestin, Christine
    Lepere, Celine
    Bachet, Jean-Baptiste
    Portales, Fabienne
    Vaillant, Jean-Nicolas
    Ychou, Marc
    Rougier, Philippe
    BMC CANCER, 2009, 9 : 347
12345